Table 1.
Selected clinical characteristics of patients with CNS myeloma
| Characteristic | N/median (%/range) |
|---|---|
| Age, in years (n=171) | |
| At myeloma diagnosis | 53 (31–82) |
| At CNS myeloma diagnosis | 56 (33–82) |
| Sex (n=171) | |
| Male | 94 (55%) |
| Female | 77 (45%) |
| Previous lines of myeloma therapy (n=172) | |
| 0 previous lines | 43 (25%) |
| 1–2 previous lines | 63 (37%) |
| >2 previous lines | 66 (38%) |
| Heavy chain isotype (n=166) | |
| IgG | 83 (50%) |
| IgA | 45 (27%) |
| IgD | 4 (2%) |
| Biclonal | 2 (1%) |
| No heavy chain | 32 (19%) |
| Light chain isotype (n=172) | |
| Kappa | 89 (52%) |
| Lambda | 73 (42%) |
| No light chain | 1 (0.6%) |
| Biclonal | 9 (5%) |
| LDH levels (n=88) | |
| Normal | 47 (53%) |
| Elevated | 41 (47%) |
| ISS stage (n=148) | |
| Stage I | 47 (32%) |
| Stage II | 61 (41%) |
| Stage III | 40 (27%) |
| Symptoms at presentation (n=146) | |
| Visual changes | 52 (36%) |
| Radiculopathy | 40 (27%) |
| Headache | 37 (25%) |
| Change in mental status | 31 (21%) |
| Peripheral neuropathy | 13 (9%) |
| Dizziness | 10 (7%) |
| Seizures | 9 (6%) |
| Auditory changes | 1 (1%) |
| FISH abnormalities | |
| Del13q | 48/122 (39%) |
| Del17p | 28/122 (23%) |
| t(4;14) | 15/122 (12%) |
| t(11;14) | 9/122 (7%) |
| Number of FISH abnormalities | |
| No abnormalities | 45/122 (37%) |
| 1 abnormality | 36/122 (30%) |
| 2 abnormalities | 23/122 (19%) |
| >2 abnormalities | 18/122 (15%) |
| CSF flow cytometry profile | |
| CD45 | 18/34 (53%) |
| CD19 | 3/34 (9%) |
| CD20 | 3/27 (11%) |
| CD4 | 0/5 (0%) |
| CD8 | 0/6 (0%) |
| CD56 | 35/50 (70%) |
| CD38 | 62/65 (95%) |
| CD138 | 31/33 (94%) |
CNS: central nervous system; Ig: immunoglobulin; ISS: International Staging System; LDH: lactate dehydrogenase